Track DOD Biotech Public , Ltd.'s receivables ($83M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for DOD.BK is $83M as of June 2026. That compares with $59M in the prior-year period — up 39.5% year over year. Investors often review this figure alongside DOD Biotech Public , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, DOD.BK's receivables moved from $59M to $83M — a 39.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DOD Biotech Public , Ltd.'s operating scale or balance-sheet position.
A receivables figure of $83M for DOD.BK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting DOD.BK's receivables ($83M), review year-over-year change from $59M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.